• Home
  • Pharmacy Medical Policy Updates

Pharmacy Medical Policy Updates

The following Pharmacy Medical Policy programs have been updated today, Feb. 1, 2021:
Effective March 1, 2021:

  • IL-4 Inhibitor
  • Oral Anticoagulant
  • SA Oncology
  • Soliris and Ultomiris
  • Amifampridine
  • Ampyra
  • Arikayce
  • ATTR Amyloidosis Onpattro
  • ATTR Amyloidosis

Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.

To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization

If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.

Institutional Providers
Professional Providers